25I-NBOMe is the substance that forced the psychedelic community to learn pharmacology the hard way. A synthetic phenethylamine derived from 2C-I with the addition of an N-2-methoxybenzyl group, it is a full agonist at the serotonin 5-HT2A receptor -- a pharmacological distinction that sounds academic until you understand what it means in practice. Classical psychedelics like LSD, psilocybin, and mescaline are all partial agonists: they activate the receptor but never push it to maximum. 25I-NBOMe slams the receptor to 85-95% of the activation that serotonin itself produces. This is the molecular reason why LSD and psilocybin have never confirmed a single pharmacological fatality in humans, while 25I-NBOMe had killed at least 38 people across Europe and the United States before most users even knew it existed.
First synthesized in 2003 by Ralf Heim at the Free University of Berlin as a radioligand for brain imaging research, 25I-NBOMe was never meant to enter a human body recreationally. The NBOMe modification increases 5-HT2A binding affinity approximately 300-fold over parent compound 2C-I, producing a substance active at microgram doses that could be laid on blotter paper and sold as LSD to buyers who had no way to distinguish the two by appearance alone. By 2010 it was flooding global drug markets. By 2013 the DEA had documented 17 American deaths and emergency-scheduled it into Schedule I. The WHO's 2016 critical review counted 21 European fatalities and 51 non-fatal poisonings. These are not overdose statistics in the way heroin produces them -- some victims took what would have been a standard recreational dose for others, because individual sensitivity varies so dramatically and unpredictably that the line between a trip and a medical emergency is invisible.
The community developed its own diagnostic in response: "if it's bitter, it's a spitter." Real LSD is tasteless or nearly so. 25I-NBOMe burns the mouth with a harsh, metallic bitterness that is unmistakable once you know what to expect. The Ehrlich reagent -- an inexpensive chemical test that turns purple in the presence of indole-containing compounds like LSD -- gives no reaction with 25I-NBOMe. These two facts have probably saved more lives than any clinical intervention. But they only help people who know them, and the fundamental problem with 25I-NBOMe has always been that its primary victims were people who thought they were taking something else entirely.
The experience itself delivers staggering visual intensity -- dense neon geometry, fluorescent color saturation, fractal cascades across every surface -- all riding on top of a body load that is genuinely punishing. Vasoconstriction grips the extremities, the heart pounds, jaw clenching is severe, and nausea comes in relentless waves. The headspace, curiously, remains relatively shallow compared to the sensory onslaught: more light show than revelation, more spectacle than insight. Duration runs 6-10 hours. For many users who sought it deliberately, the consensus is that the physical cost is too high for what the experience delivers. For the many who received it unknowingly as fake LSD, the consensus is darker.
Safety at a Glance
High Risk- Reagent Test Everything Sold as LSD
- Drop Ehrlich reagent on a small piece of the blotter
- Toxicity: Fatality Profile 25I-NBOMe is among the most dangerous psychedelics ever to reach widespread recreational use. The WH...
- Dangerous with: Cocaine
- Overdose risk: Recognizing NBOMe Overdose 25I-NBOMe overdose is a life-threatening medical emergency fundamental...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
sublingual
insufflated
Duration
sublingual
Total: 6 hrs – 10 hrsinsufflated
Total: 4 hrs – 6 hrsHow It Feels
The first thing you notice is the taste. Within seconds of placing the blotter under your tongue, a harsh, bitter, metallic burn floods your mouth -- nothing like the subtle paper-and-ink flavor of actual LSD. It numbs the tissue where it sits and lingers stubbornly even after the blotter is removed. If you did not know what you were taking, this is your warning. If you did know, you settle in and wait.
The come-up hits like a switch being thrown. Fifteen minutes in, a surging wave of stimulant energy pours through the body with startling force. The heart hammers. Blood pressure spikes. Vasoconstriction seizes the extremities -- fingers go cold and pale, toes tingle, and there is a tightness across the chest that demands conscious attention to breathing. The visual field starts to fragment and rearrange itself before the body has had any time to adjust to the physical onslaught. This is not a gentle psychedelic onset. There is no easing in. The substance announces itself with the subtlety of a fire alarm.
By thirty minutes the visuals have reached an intensity that is genuinely difficult to overstate. Every surface in the environment erupts with dense, intricate, rapidly shifting geometric patterns -- crystalline fractals, spiraling mandalas, tessellating grids rendered in hyper-saturated neon colors that seem to generate their own luminescence. The world looks as though it has been rebuilt from scratch using mathematics and fluorescent pigment. Afterimages are intense and persistent, creating overlapping layers of visual data that make navigation difficult. Faces morph and distort dramatically. At moderate doses, the visual intensity of 25I-NBOMe genuinely exceeds what most classical psychedelics can achieve at any dose. If you want to understand what "psychedelic visuals" look like cranked to their theoretical maximum, this is probably it.
The body load is the defining challenge. Vasoconstriction is persistent and can become alarming -- not abstract anxiety but a concrete physical sensation of blood retreating from your hands and feet, a tight band of pressure around the chest, fingertips going white. Nausea arrives in powerful waves. Jaw clenching is severe and involuntary, worse than MDMA for many people. The stimulant energy is enormous and relentless, making stillness feel impossible while making coordinated movement difficult. Despite all this physical bombardment, the headspace remains curiously shallow. Thoughts are rapid and somewhat scattered but lack the profound ego dissolution, emotional depth, or revelatory insight that characterizes LSD or psilocybin at comparable intensity levels. The experience is more spectacle than journey -- a dazzling, physically punishing light show playing out across the surface of consciousness without ever really reaching the depths.
The peak sustains for three to four hours and the total experience stretches six to ten hours. The descent is slow and often uncomfortable, with residual vasoconstriction and stimulant jitteriness persisting long after the visual fireworks have dimmed. The aftermath includes headache, muscle soreness from sustained tension, deep exhaustion, and a flat, depleted mood that can linger into the next day. Sleep remains elusive for hours after the visuals have faded. There is no warm afterglow, no gentle reintegration. The overall impression is of overwhelming sensory power delivered at a significant physical cost -- a substance that showed you something extraordinary and charged your body heavily for the privilege.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(27)
- Abnormal heartbeat— Abnormal heartbeat (arrhythmia) is any deviation from the heart's normal rhythm — including beats th...
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
- Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased bodily temperature— Increased bodily temperature (hyperthermia) is an elevation of core body temperature above the norma...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
- Mouth numbing— Mouth numbing is a localized loss of sensation in the tongue, gums, cheeks, and surrounding oral tis...
- Muscle cramp— Muscle cramps are sudden, involuntary, and often painful contractions of muscles that occur as a sid...
- Muscle tension— Persistent partial contractions or tightening of muscles that produces uncomfortable stiffness, cram...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Restless legs— Restless legs is an uncomfortable neurological effect characterized by an irresistible compulsion to...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Stomach cramp— Stomach cramps are sharp, intermittent pains in the abdominal region that can occur when psychoactiv...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Cognitive & Perceptual Effects
Visual(22)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour replacement— A visual phenomenon in which the colors of objects or the entire visual field are statically replace...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Frame rate suppression— Perception of visual motion as choppy discrete frames rather than smooth continuous flow, resembling...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Magnification— A visual distortion in which objects appear larger or closer than they actually are, as though one's...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Recursion— The visual field begins to repeat and nest within itself in a self-similar, fractal-like manner, as ...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(20)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Feelings of impending doom— Feelings of impending doom is the sudden onset of an overwhelming, visceral certainty that something...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Panic attack— A panic attack is a discrete episode of acute, overwhelming fear or terror that arises suddenly and ...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Multi-sensory(6)
- Dosage independent intensity— Dosage independent intensity is the uncommon and poorly understood phenomenon in which a person expe...
- Gustatory hallucination— Gustatory hallucinations are phantom taste experiences in which distinct flavors manifest in the mou...
- Machinescapes— Machinescapes are complex multisensory hallucinations involving the perception of enormous mechanica...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Sensory overload— An overwhelming flood of sensory information that exceeds the brain's ability to process, creating a...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(3)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
25I-NBOMe is a full agonist at the serotonin 5-HT2A receptor with subnanomolar binding affinity (Ki approximately 0.5-1.6 nM depending on assay conditions). This is the single most important fact about its pharmacology and the root cause of everything that makes it more dangerous than classical psychedelics. LSD, psilocybin, DMT, and mescaline are partial agonists at 5-HT2A -- they activate the receptor but produce submaximal stimulation even when every available receptor is occupied. 25I-NBOMe achieves 85-95% of the maximal response that serotonin itself produces in functional assays. In pharmacological terms, it has a much higher intrinsic efficacy. In human terms, it pushes the system harder than it was ever designed to be pushed.
The NBOMe Pharmacophore
The parent compound 2C-I (4-iodo-2,5-dimethoxyphenethylamine) is a moderately potent psychedelic active in the 10-30 mg range. Ralf Heim's 2003 modification -- attaching a 2-methoxybenzyl group to the terminal nitrogen -- increased 5-HT2A binding affinity by approximately 300-fold. This dramatic enhancement occurs because the N-benzyl group inserts into an auxiliary hydrophobic pocket in the receptor that simpler phenethylamines cannot reach. Bryan Roth's laboratory at the University of North Carolina subsequently confirmed the receptor pharmacology of the entire NBOMe series, mapping their binding profiles across multiple serotonin receptor subtypes. The structural insight here is that a single molecular appendage transforms a milligram-dose psychedelic into a microgram-dose one while simultaneously converting it from partial to full agonism -- a combination that creates the narrow safety margin.
Receptor Selectivity
Beyond 5-HT2A, 25I-NBOMe binds with high affinity to 5-HT2C (Ki approximately 4.6-130 nM, study-dependent) and has lower but meaningful affinity at 5-HT2B, 5-HT1A, and dopamine D2 receptors. The 5-HT2A/5-HT2C affinity ratio contributes to its pronounced stimulant character and peripheral vasoconstrictive effects. The 5-HT2B activity, while less studied, is potentially relevant to cardiovascular toxicity given the precedent of fenfluramine-induced valvulopathy via chronic 5-HT2B activation.
Peripheral Vasoconstriction
5-HT2A receptors are expressed on vascular smooth muscle cells throughout the body. When a full agonist with subnanomolar affinity floods these receptors, the result is sustained, intense vasoconstriction that partial agonists like LSD simply cannot produce to the same degree. This is the mechanism behind the hypertension, tachycardia, cold/numb extremities, and cardiovascular collapse seen in acute toxicity cases. It is also why combining 25I-NBOMe with any stimulant is particularly lethal -- you are stacking two vasoconstrictive mechanisms on top of each other.
Neurotoxicity
In vitro studies using SH-SY5Y human neuronal cell models have demonstrated that 25I-NBOMe causes dose-dependent neurotoxicity: increased reactive oxygen species production, mitochondrial membrane depolarization, and apoptotic cell death. These effects were not observed with classical psychedelics at comparable concentrations. Whether this translates to neurotoxicity at recreational doses in humans remains unconfirmed, but the in vitro signal is concerning and distinguishes NBOMe from the remarkably clean neurotoxicity profiles of LSD and psilocybin.
Pharmacokinetics
Absorption is primarily sublingual, with onset in 15-45 minutes and peak effects at 1-2 hours. Oral bioavailability is poor due to first-pass hepatic metabolism, which is why it is laid on blotter paper for sublingual absorption rather than pressed into pills. Nasal insufflation produces dramatically faster absorption and higher peak concentrations -- this route is responsible for a disproportionate share of fatalities. Total duration is 6-10 hours. Hepatic metabolism likely involves CYP450-mediated O-demethylation and hydroxylation. The compound is detectable postmortem in blood, urine, vitreous humor, and tissue via LC-MS/MS.
Detection Methods
Urine Detection
25I-NBOMe is not targeted by standard immunoassay-based urine drug screens. However, due to its phenethylamine backbone, there is a theoretical possibility of cross-reactivity with amphetamine immunoassays, though this has not been consistently reported in clinical literature. Specialized LC-MS/MS methods developed for novel psychoactive substances can detect NBOMe compounds and their metabolites in urine for approximately 24 to 48 hours after ingestion, depending on dose and individual metabolism.
Blood and Serum Detection
Blood detection windows for 25I-NBOMe are relatively short. Peak plasma concentrations occur within 30 minutes to 2 hours depending on the route of administration (sublingual absorption is typical for NBOMe compounds). Blood concentrations fall below detectable thresholds within 6 to 16 hours for most methods. LC-MS/MS remains the only reliable analytical approach for serum detection, as the doses involved (typically hundreds of micrograms to low milligrams) produce low absolute concentrations.
Standard Drug Panel Inclusion
25I-NBOMe is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. It is not specifically targeted by any routine workplace or clinical immunoassay. While some structural similarity to amphetamines exists, cross-reactivity on amphetamine panels is inconsistent and cannot be relied upon for either detection or exclusion. Identification requires specific testing at a reference laboratory equipped for novel psychoactive substance analysis.
Confirmatory Methods
Definitive identification of 25I-NBOMe requires LC-MS/MS or high-resolution mass spectrometry (HRMS). GC-MS can also be employed but may require derivatization due to the thermal lability of NBOMe compounds. Reference standards are necessary for quantitative confirmation. Forensic and clinical toxicology laboratories that maintain novel psychoactive substance panels are the only facilities reliably capable of this analysis.
Reagent Testing (Harm Reduction)
Reagent testing is critically important for NBOMe compounds due to their significantly higher toxicity profile compared to classical psychedelics. The Ehrlich reagent shows NO reaction with 25I-NBOMe, which is the single most important distinguishing test: any substance sold as a psychedelic that fails to turn purple with Ehrlich may be an NBOMe compound rather than LSD or a tryptamine. The Marquis reagent produces variable results depending on the specific NBOMe compound, ranging from no reaction to green or brown color changes. The Mecke reagent may produce a brown or dark green reaction. For harm reduction purposes, always testing with Ehrlich first is essential. The absence of a purple Ehrlich reaction is a strong warning sign that the substance is not a lysergamide or tryptamine and may be a potentially dangerous NBOMe compound.
Interactions
| Substance | Status | Note |
|---|---|---|
| Cocaine | Unsafe | — |
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 2C-T-x | Uncertain | — |
| Caffeine | Uncertain | — |
| Cannabis | Uncertain | — |
| DOx | Uncertain | — |
| MDMA | Uncertain | — |
History
Synthesis and Original Purpose (2003)
25I-NBOMe was first synthesized in 2003 by Ralf Heim at the Free University of Berlin as part of his doctoral dissertation on potent 5-HT2A receptor agonists. Heim was working on developing radioligand tools for positron emission tomography (PET) brain imaging -- substances that bind tightly to specific receptors so their distribution can be mapped in living brains using radioactive tracers. The NBOMe modification (adding a 2-methoxybenzyl group to the nitrogen of the phenethylamine scaffold) dramatically increased 5-HT2A binding affinity, making the compound useful for receptor mapping research. It was a laboratory tool, never intended for human consumption.
Pharmacological Characterization (2006-2010)
David Nichols' laboratory at Purdue University and Bryan Roth's group at the University of North Carolina subsequently characterized the receptor pharmacology of the NBOMe series in detail, publishing binding affinity data and functional assay results that confirmed 25I-NBOMe as an exceptionally potent full agonist at 5-HT2A. These publications, intended for the scientific community, inadvertently provided a recipe book for clandestine chemists seeking the next marketable research chemical.
Emergence on Drug Markets (2010-2012)
25I-NBOMe appeared on recreational drug markets around 2010, initially sold openly on research chemical vendor sites and subsequently as fake LSD. Its microgram-range dosing meant it could be laid on blotter paper indistinguishable from LSD tabs. The price was a fraction of actual LSD. By 2012, poison control centers across the United States, Europe, and Australia were reporting a surge in NBOMe-related hospitalizations. Emergency physicians were encountering a clinical presentation -- seizures, hyperthermia, rhabdomyolysis -- unlike anything they had seen from classical psychedelics.
Fatalities and Emergency Scheduling (2012-2013)
The death toll mounted rapidly. In the United States, the DEA documented at least 17 deaths, 14 from acute pharmacological toxicity and 3 from fatal trauma during episodes of extreme agitation. In November 2013, the DEA used its emergency scheduling authority to place 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe into Schedule I. The WHO Expert Committee on Drug Dependence's 2016 critical review identified 21 fatalities and 51 non-fatal intoxications across Europe. Additional deaths were documented in Australia, Brazil, and multiple other countries.
Legal Status and Ongoing Prevalence (2013-Present)
25I-NBOMe is now Schedule I in the United States (permanently scheduled 2016), Class A in the United Kingdom, and controlled in most European Union nations and Australia. Despite scheduling, it continues to appear in drug seizures and poison control reports, though at lower frequency than its peak years of 2012-2013. The harm reduction infrastructure that grew in response -- widespread Ehrlich reagent promotion, the "bitter spitter" meme, festival drug checking services -- has become a permanent feature of psychedelic community culture. 25I-NBOMe's legacy is not as a recreational drug but as the substance that taught a generation of psychedelic users that testing their drugs is not optional.
Harm Reduction
Reagent Test Everything Sold as LSD
This is the single most important harm reduction practice in psychedelics, full stop. 25I-NBOMe is routinely sold as LSD on blotter paper that looks identical to the real thing. The Ehrlich reagent test takes two minutes and costs under a dollar per use:
- Drop Ehrlich reagent on a small piece of the blotter
- LSD and other indole compounds (psilocybin, DMT) turn the reagent purple/violet within minutes
- 25I-NBOMe produces no color change -- the reagent stays yellow
- A negative Ehrlich result on blotter means it is not LSD and should not be consumed
- Marquis reagent provides additional confirmation: NBOMe compounds produce a green-brown reaction distinct from LSD's olive-black
Ehrlich kits are legal everywhere, inexpensive, and available from DanceSafe, Bunk Police, and most harm reduction organizations. There is no rational argument against testing.
If It Is Bitter, Spit It Out
Real LSD is tasteless or has a faint metallic quality from the ink on the blotter. 25I-NBOMe produces an immediate, unmistakable bitter chemical burn that numbs the tongue. The community maxim "if it's bitter, it's a spitter" exists because this taste test has saved lives. It is not a substitute for reagent testing, but it provides a last line of defense when a tab is already in your mouth.
Never Insufflate
Nasal insufflation of powdered 25I-NBOMe produces rapid absorption, dramatically higher peak plasma concentrations, and has been directly linked to multiple fatalities -- particularly in Australia where several young people died after snorting NBOMe powder. The margin between an active dose and a dangerous dose is already razor-thin via sublingual administration. Insufflation eliminates that margin entirely.
Dosing Is Guesswork and That Is the Problem
There is no established safe dose of 25I-NBOMe. Recreational doses reportedly range from 200-1200 µg sublingual, but fatal outcomes have occurred within this range. Individual sensitivity varies so dramatically that the same dose producing mild effects in one person has caused seizures and death in another. Blotter potency is unverified. If you have made the informed decision to use this substance despite the risks:
- Start with the smallest possible portion of a blotter
- Wait the full onset period (45-120 minutes) before making any assessment about intensity
- Never redose -- effects may still be building long after you expect them to have peaked, and premature redosing has contributed directly to overdoses and deaths
Dangerous Combinations
- Stimulants (amphetamine, cocaine, MDMA) -- stacks vasoconstriction and cardiovascular strain; the combination has been implicated in fatalities
- MAOIs -- potentially fatal serotonergic potentiation
- Lithium -- dramatically lowers seizure threshold with serotonergic psychedelics; potentially lethal
- Cannabis -- unpredictably intensifies effects and increases anxiety, paranoia, and cardiovascular load
- Tramadol -- lowers seizure threshold; contraindicated with all serotonergic psychedelics
- Alcohol -- impairs recognition of dangerous physical symptoms
Emergency Response
If someone shows signs of NBOMe toxicity -- seizures, extreme agitation, rigid muscles, very high body temperature, loss of consciousness, blue/cold extremities -- call emergency services immediately. This is not a bad trip that will pass. It is a medical emergency with a documented fatality rate. While waiting:
- Place the person in the recovery position if unconscious
- Remove excess clothing and actively cool the body if temperature is elevated
- Do not attempt physical restraint unless absolutely necessary to prevent self-harm -- restraint worsens rhabdomyolysis and hyperthermia
- Tell paramedics what was taken; Good Samaritan laws protect callers in most jurisdictions
Toxicity & Safety
Fatality Profile
25I-NBOMe is among the most dangerous psychedelics ever to reach widespread recreational use. The WHO Expert Committee on Drug Dependence (38th meeting, 2016) documented 21 deaths and 51 non-fatal intoxications across Europe. The U.S. DEA documented at least 17 deaths prior to emergency scheduling in November 2013, with 14 attributed to direct pharmacological toxicity and 3 to fatal trauma during episodes of uncontrolled agitation. Additional fatalities have been confirmed in Australia, Brazil, and other countries. This death toll stands in stark contrast to classical psychedelics -- LSD and psilocybin have zero confirmed pharmacological fatalities in recorded medical history.
Why It Kills: Full Agonism and Vasoconstriction
The lethality stems from two pharmacological properties acting in concert. First, as a full 5-HT2A agonist, 25I-NBOMe produces maximal receptor activation -- a level of stimulation that partial agonists like LSD are structurally incapable of reaching. Second, 5-HT2A receptors on vascular smooth muscle cells throughout the body respond to this full agonism with intense, sustained vasoconstriction. The combination produces a cascade of systemic toxicity that the body's compensatory mechanisms cannot contain at threshold-crossing doses.
Acute Toxicity Presentations
Clinical analysis of NBOMe intoxication cases reveals a consistent syndrome combining features of serotonin toxicity and sympathomimetic crisis:
- Cardiovascular: Hypertension (73% of documented cases), tachycardia (95%), and cardiovascular collapse in severe presentations
- Neurological: Seizures (45% of cases), including progression to status epilepticus (continuous seizure activity); myoclonus, muscle rigidity, tremor
- Thermoregulatory: Hyperthermia often exceeding 40°C/104°F, contributing directly to multi-organ failure
- Muscular: Rhabdomyolysis -- breakdown of skeletal muscle tissue releasing myoglobin into the bloodstream, which deposits in and destroys kidney tubules
- Psychiatric: Severe agitation (77%), hallucinations (76%), delirium, "excited delirium" with aggressive and self-harmful behavior
- Metabolic: Metabolic acidosis, disseminated intravascular coagulation (DIC)
- Organ failure: Acute renal failure from rhabdomyolysis, hepatic failure, multi-organ dysfunction syndrome (MODS)
The Fatal Cascade
Published forensic case reports describe a characteristic progression: initial psychedelic effects escalate into uncontrollable agitation, followed by seizure activity (often prolonged status epilepticus), severe hyperthermia, rhabdomyolysis, and ultimately cardiovascular collapse or multi-organ failure. In one documented case series, continuous sedation and neuromuscular blockade were required for several days to control persistent seizure activity. The entire cascade can unfold in hours.
Dose-Response Unpredictability
The most dangerous feature of 25I-NBOMe is not its absolute toxicity but its unpredictability. The dose-response curve is steep and individual sensitivity varies dramatically. There is no threshold below which toxicity is reliably avoided. Fatal outcomes have occurred at doses within the reported recreational range. No controlled human dose-finding studies exist. Every use is a gamble with unknown odds.
In Vitro Neurotoxicity
Cell culture studies using SH-SY5Y human neuronal models show dose-dependent neurotoxicity from 25I-NBOMe exposure: elevated reactive oxygen species, mitochondrial depolarization, and apoptotic cell death. These effects were absent with LSD and psilocybin at equivalent concentrations, suggesting a neurotoxic potential that classical psychedelics do not share.
Postmortem Detection
25I-NBOMe has been detected in blood, urine, vitreous humor, and organ tissue samples using LC-MS/MS in forensic cases. Standard hospital immunoassay drug screens do not detect it -- specialized toxicology testing is required. This has likely led to underreporting of NBOMe-related deaths where specialized testing was not performed.
Addiction Potential
25I-NBOMe is not addictive in the classical pharmacological sense. It produces no physical dependence, no withdrawal syndrome, and no compulsive self-administration in animal models -- characteristics shared across the serotonergic psychedelic class. Rapid tolerance develops within 24-48 hours of a single dose, making consecutive daily use pointless as effects diminish sharply. Full cross-tolerance exists with LSD, psilocybin, mescaline, and other 5-HT2A-mediated psychedelics, further preventing substitution patterns. Tolerance resets to baseline within approximately 5-7 days. The nature of the experience itself -- physically punishing, mentally exhausting, and often genuinely frightening -- does not promote the kind of positive reinforcement that drives compulsive redosing with stimulants or opioids. The substance's primary risk was never addiction but acute toxicity from a single exposure, a pattern more reminiscent of poisoning than of substance use disorder.
Overdose Information
Recognizing NBOMe Overdose
25I-NBOMe overdose is a life-threatening medical emergency fundamentally different from a "bad trip" on classical psychedelics. With LSD or psilocybin, overdose management centers on psychological support and benzodiazepines for anxiety. With 25I-NBOMe, the emergency is primarily physiological -- seizures, hyperthermia, and organ failure are the immediate threats, and minutes matter.
Warning Signs Requiring Immediate Emergency Response
- Seizures or uncontrollable muscle jerking
- Extreme agitation with aggressive or self-harmful behavior ("excited delirium")
- Body temperature that is obviously and dangerously elevated (skin hot to touch, profuse sweating or paradoxical absence of sweating)
- Blue, cold, or numb extremities that do not improve
- Rigid muscles, especially combined with elevated temperature
- Loss of consciousness or complete unresponsiveness
- Chest pain or difficulty breathing
Any of these warrant an immediate 911/999/112 call. Do not wait to see if it passes. It may not.
The Fatal Progression
Documented fatal cases follow a characteristic sequence:
- Initial phase: Intense agitation, aggression, visual and auditory hallucinations, tachycardia, hypertension, dilated pupils
- Escalation: Generalized tonic-clonic seizures progressing to status epilepticus
- Systemic crisis: Severe hyperthermia (>40°C/104°F), rhabdomyolysis (muscle breakdown releasing myoglobin), metabolic acidosis
- Organ failure: Acute kidney injury from myoglobin deposition, hepatic failure, disseminated intravascular coagulation
- Death: From multi-organ dysfunction, cardiac arrest, or sustained status epilepticus
This sequence can complete in hours. It is not a slow deterioration. It is a cascade.
What to Do While Waiting for Paramedics
- Place the person in the recovery position if unconscious or seizing
- Actively cool the body: remove excess clothing, apply cold wet towels or ice packs to neck, armpits, and groin
- Do not restrain the person physically unless absolutely necessary -- physical restraint dramatically worsens rhabdomyolysis and hyperthermia
- Do not put anything in the mouth of someone who is seizing
- Tell paramedics exactly what was taken, when, and how much if known
- Good Samaritan laws protect callers in most U.S. states and many other jurisdictions
Hospital Management
There is no antidote. Treatment is entirely supportive:
- Seizures: IV benzodiazepines first-line (diazepam, midazolam, lorazepam). Refractory status epilepticus may require propofol, barbiturate infusion, or neuromuscular blockade
- Hyperthermia: Aggressive external cooling (ice packs, evaporative cooling, cold IV fluids). Antipyretics like ibuprofen and acetaminophen are ineffective because the hyperthermia is not prostaglandin-mediated
- Rhabdomyolysis: Aggressive IV fluid resuscitation, monitoring of creatine kinase, electrolytes, and renal function
- Cardiovascular: IV fluids for hypotension; short-acting antihypertensives for dangerous blood pressure elevation; beta-blockers are avoided due to risk of unopposed alpha-adrenergic vasoconstriction
- Agitation: High-dose benzodiazepines preferred over antipsychotics
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Tolerance
| Full | almost immediately after ingestion |
| Half | 1 week |
| Zero | 2 weeks |
Cross-tolerances
Legal Status
Regulatory Status
25I-NBOMe is among the most widely controlled novel psychoactive substances globally, with explicit scheduling in numerous countries following a wave of documented fatalities.
United States
The DEA placed 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe under emergency Schedule I control onNovember 15, 2013, pursuant to the temporary scheduling authority under 21 U.S.C. section 811(h), citing an "imminent hazard to the public safety" . The temporary order was extended in 2015, and 25I-NBOMe waspermanently placed in Schedule I effectiveOctober 27, 2016 (81 FR 78710) . It is now listed with CSA code 7538.
Manufacturing, distributing, dispensing, or possessing 25I-NBOMe carries the same federal penalties as other Schedule I substances, including up to 20 years imprisonment for distribution and up to 1 year for simple possession (first offense).
United Nations
As of the 2016 WHO Expert Committee on Drug Dependence (ECDD) critical review, 25I-NBOMe was not listed for control under the 1961 Single Convention on Narcotic Drugs or the 1971 Convention on Psychotropic Substances, though the ECDD recommended its international scheduling. The substance has been assessed by the UN system for potential future inclusion in international drug control schedules .
Other Major Jurisdictions
- United Kingdom:Class A controlled substance under the Misuse of Drugs Act 1971, carrying maximum penalties of 7 years for possession and life imprisonment for supply.
- Germany: Controlled under theNpSG (Neue-psychoaktive-Stoffe-Gesetz) and also captured under Anlage I BtMG provisions.
- Canada: Controlled underSchedule III of the Controlled Drugs and Substances Act as part of the broader phenethylamine scheduling.
- Australia:Schedule 9 (prohibited substance) under the Poisons Standard.
- Russia: Included inList I of controlled narcotic substances and psychotropic substances.
- Japan: Controlled as a designated substance under the Pharmaceutical and Medical Device Act.
- Sweden, Denmark, Norway: Specifically scheduled under national controlled substance legislation.
- Brazil, Israel, Poland, Italy: Specifically controlled under national NPS or drug control legislation.
References
DEA. Schedules of Controlled Substances: Temporary Placement of Three Synthetic Phenethylamines Into Schedule I. 78 FR 68716 (October 10, 2013). DEA. Schedules of Controlled Substances: Placement of Three Synthetic Phenethylamines Into Schedule I. 80 FR 70657 (November 13, 2015). WHO ECDD. 25I-NBOMe Critical Review, 38th Meeting, Geneva, 2016.
Experience Reports (4)
Tips (9)
25I-NBOMe is frequently sold as LSD. The telltale signs are a strong bitter metallic taste that numbs your tongue and mouth. If a blotter tastes noticeably bitter, spit it out immediately. Real LSD is tasteless or has only a faint paper taste.
An Ehrlich reagent test kit is essential if you are buying blotter psychedelics. 25I-NBOMe will not react with Ehrlich reagent, while LSD will turn purple. This simple 2-dollar test can literally save your life.
25I-NBOMe has been linked to multiple deaths and hospitalizations. It can cause seizures, hyperthermia, and cardiovascular emergencies even at doses only slightly above common recreational levels. The margin of safety is very narrow compared to classical psychedelics.
Have a trip sitter present, ideally someone with psychedelic experience. They should remain calm and reassuring without being intrusive. A good sitter can make the difference between a challenging experience and a genuine crisis.
If you knowingly choose to take 25I-NBOMe, never take more than one blotter tab and never insufflate it. The difference between a recreational dose and a medical emergency can be as small as a few hundred micrograms. Dose-response curves for NBOMe compounds are extremely steep.
Significant vasoconstriction is common with 25I-NBOMe. If you experience numbness, blue or cold extremities, severe headache, or chest pain, seek medical attention immediately. Do not take vasoconstrictive substances like stimulants alongside NBOMe compounds.
Community Discussions (6)
See Also
Same Class
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 25I-NBOMe - TripSit Factsheet
TripSit factsheet for 25I-NBOMe
tripsit - 25I-NBOMe - Wikipedia
Wikipedia article on 25I-NBOMe
wikipedia